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Abstract
Introduction: Ankylosing spondylitis (AS) is an idiopathic chronic inflammatory disease that has prominent effects on the spine and
peripheral joints. In addition, extraarticular manifestations such as enthesitis and acute anterior uveitis may be clinically important. In
recent years, the therapy of AS has changed, largely due to the introduction of inhibitors of the proinflammatory cytokine tumor necrosis
factor (TNF). Adalimumab, a human monoclonal antibody specifically for TNF, is the most recent of the TNF blocking agents that have
been approved for the treatment of active, nonsteroidal antiinflammatory drug (NSAID)-refractory patients with AS.
Aims: To evaluate the evidence for the therapeutic value of adalimumab in ankylosing spondylitis.
Evidence review: There is clear evidence that adalimumab, administered 40 mg subcutaneously every 2 weeks, substantially improves
the signs and symptoms of NSAID-refractory, active AS when compared with placebo treatment. There is ample evidence that
adalimumab causes significant improvements in physical health status and overall AS-specific, health-related quality of life and physical
functioning, which consequently leads to better work productivity. There is substantial evidence that adalimumab improves spinal and
sacroiliac joint inflammation in AS patients. Initial results from clinical trials suggest that there is no increased risk of serious infections
or malignancies in adalimumab-treated patients with AS. The most common adverse events were injection-site reactions. Limited
economic evidence suggests that adalimumab 40 mg may be cost effective when used according to current valid treatment guidelines.
Place in therapy: Adalimumab is an effective treatment for patients with active AS.
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Core evidence place in therapy summary for adalimumab in ankylosing spondylitis
Outcome measure Evidence Implications
Patient-oriented evidence
Quality of life Substantial Adalimumab improves quality of life, physical functioning, and work productivity
Tolerability Clear Adalimumab has an acceptable tolerability profile
Disease-oriented evidence
ASAS criteria Clear Adalimumab produces significant improvement after 24 weeks; improvement is maintained for up to
2 years
BASDAI criteria Clear Adalimumab produces significant improvement after 24 weeks; improvement is maintained for up to
2 years
Remission Clear Adalimumab produces partial remission for up to 2 years
Spinal and sacroiliac joint
inflammation measured by MRI
Substantial Adalimumab reduces inflammation for up to 1 year
Economic evidence
Cost effectiveness Limitied Adalimumab is a cost-effective treatment for AS compared with conventional therapy, however, high
acquisition costs remain a concern
AS, ankylosing spondylitis; ASAS, ASsessment in Ankylosing Spondylitis; BASDAI, Bath AS Disease Activity Index; MRI, magnetic resonance imaging.Scope, aims, and objectives
Ankylosing spondylitis (AS) is a chronic inflammatory disease of
the spine and the peripheral joints. AS is mostly characterized
by pain and stiffness of the spine, but many patients can have
large- joint arthritis, enthesitis, and progressive deformities that
often lead to significant disability if left untreated. Until recently,
therapeutic options have been relatively limited for patients with
AS. Conventional treatment options include nonpharmacologic
modalities such as physiotherapy, and nonsteroidal
antiinflammatory drugs (NSAIDs). For patients with peripheral
arthritis, a class of drugs also used for patients with rheumatoid
arthritis (RA), commonly referred to as disease-modifying
antirheumatic drugs (DMARDs), has been tried in AS. Although
these modalities may have some effect on pain and other
symptoms, none of these drugs have been shown to alter the
progression of the disease, particularly for spinal disease. A
major change in the therapeutic approach to AS came with the
introduction of inhibitors of tumor necrosis factor (TNF). To date,
three TNF inhibitors have proven to have efficacy in the
treatment of AS patients with active NSAID-refractory disease,
and demonstrated improvements in signs and symptoms,
magnetic resonance imaging (MRI) assessments, and in
measures of functional status and quality of life (QOL).
Adalimumab (Humiraﾮ, Abbott), a human monoclonal antibody
that binds specifically to TNF, is the most recent of the TNF
blocking agents that have been approved for AS in 2006, both
in Europe and the US. The objective of this article is to review
the clinical evidence base for the use of adalimumab specifically
for AS.
Methods
The English language medical literature was searched in August
2007 in the following databases. The search strategy was
“adalimumab in ankylosing spondylitis” for articles published
from January 1990 to July 2007 (inclusive). Nonhuman and in-
vitro studies were excluded from the search.
• PubMed, http://www.ncbi.nlm.nih.gov
• EMBASE, http://www.datastarweb.com
• BIOSIS, http://www.datastarweb.com
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• York University Centre for Reviews and Dissemination
databases, http://www.york.ac.uk/inst/crd/crddatabases.htm
• NHS Health Technology Assessment Programme,
http://www.hta.nhsweb.nhs.uk
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index.htm
• EULAR, http://www.abstracts2view.com/eular/sessionindex.php
A total of 77 publications (excluding guidelines) were identified
from the search strategy (Table 1). Following the search and
manual checking of the references, 17 full papers and 15 meeting
abstracts were included in the evidence base.
Disease overview
AS is a chronic inflammatory rheumatic disease typically affecting
the sacroiliac joints and the axial skeleton. The hallmark of AS is
inflammation of the sacroiliac joints, followed by inflammation
rising along the spine leading to back pain and progressive
stiffness. This is accompanied by the formation of
syndesmophytes (bone outgrowths of the spine). Enthesitis, or
inflammation of the entheses (the site of insertion of ligaments,
tendons, and other tissue into bone), is another typical feature of
AS that can contribute to new bone development and joint
fixation (ankylosis). Arthritis of extraaxial joints, in particular the
hips, shoulders, and knees, can also lead to progressive
deformities and disability. Associated extraarticular
manifestations include acute anterior uveitis, cardiovascular and
pulmonary abnormalities, neurologic sequelae, and both clinical
and subclinical gastrointestinal (GI) findings.
AS is considered the prototypical condition among a group of
related conditions known as the spondyloarthropathies (SpA);
others include reactive arthritis, enteropathic arthritis, psoriatic
arthritis with axial involvement, undifferentiated spondyloarthritis,
and juvenile spondyloarthropathy. Although symptoms can occur
at any stage of life, AS typically affects young adults with a peak
age of onset between 20 and 30 years. AS is the most frequent
subtype of SpA, being more prevalent than previously thought,
with an estimated prevalence as high as 1% in Caucasians and
approximately 0.5% among the general population (Sieper et al.
2006). The presence of HLA-B27 is strongly associated with AS;
for example, it is found in about 95% of patients with AS in the
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Category Number of records
Full papers Abstracts
Initial search 77 53
records excluded 49 38
records included 13 15
Additional studies identified 40
Level 1 clinical evidence
(systematic review, meta analysis)
41
Level 2 clinical evidence (RCT) 36
Level ≥3 clinical evidence 44
trials other than RCT 44
case studies 00
Economic evidence 20
Total records included 17 15
For definitions of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website (http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review297
US, Europe, and China (Feltkamp et al. 2001). Moreover, there is
an association of AS and HLA-B27 in most other ethnic
groups worldwide.
The clinical course of AS is variable and is typically characterized
by mild or moderate flares of active disease, alternating with
periods of near or total quiescence. While some patients have
mild impairment that adequately responds to mild therapeutic
interventions, others can have a severe disease with spinal fusion,
progressive deformities, and pronounced incapacity. Evidence is
growing that even in its less severe form, many affected patients
manifest significant radiographic joint damage, functional
impairment, reduced QOL, and long-term work disability (Chorus
et al. 2003; van Denderen et al. 2005).
The societal and economic burden of AS can be considerable.
Due to a general occurrence in the third decade of life, the age at
which many individuals are developing their maximal earning
ability, in combination with the progressive nature of the disease,
particularly in cases of continuous disease activity, AS often
impairs functional ability and leads to increasing disability and
loss of employment. High disease activity and poor physical
function have been identified as important determinants of costs
(Boonen 2006).
In recent years, advances in the understanding of immune-
mediated disorders, combined with progress in biotechnology,
have led to the development of novel therapeutic agents. These
so-called biologic agents, particularly the inhibitors of the
proinflammatory cytokine TNF, have proven to be highly effective
in patients with AS. The success of these agents has
fundamentally altered the clinical approach to patients. In addition
to their positive effects on signs and symptoms of AS, TNF
inhibitors may offer positive impacts on the societal and
economic burden of the disease.
Current therapy options
Until the introduction of biologics, therapeutic options for AS
patients were relatively limited. As with all forms of arthritis, the
primary treatment goals for AS include reduction in pain,
improvement of function and mobility, psychosocial functioning,
and enhancement in overall QOL. These objectives are sought
in all AS patients using both pharmacologic and non-
pharmacologic modalities.
Various criteria have been used to assess clinical response in AS.
The Bath AS Disease Activity Index (BASDAI) consists of six
questions measuring the severity of fatigue, spinal pain,
peripheral joint pain, tenderness, and stiffness on a visual analog
scale (VAS) (0–10). A >50% improvement in BASDAI is considered
clinically relevant.
The ASsessment in Ankylosing Spondylitis International Working
Group criteria or ASAS20 response criteria are now used more
often (Brandt et al. 2004). An ASAS20 responder is defined as a
patient experiencing improvement of at least 20% and an
absolute improvement of at least 1 unit (on a 0–10 scale)
compared with baseline in at least three of the following four
domains, with no deterioration (defined as a worsening of at least
20% or an absolute increase of at least 1 unit) in the remaining
domain: patient’s global assessment of disease activity as
assessed by a VAS; patient’s assessment of pain represented by
a total back pain score as assessed by VAS; patient function as
assessed by the Bath Ankylosing Spondylitis Functional Index
(BASFI) score (VAS) (Calin et al. 1994); and inflammation,
represented most frequently by the mean of the severity and
duration of morning stiffness as assessed by questions five and
six of the BASDAI score (VAS). Similarly, the ASAS40 response
represents improvement of at least 40% and an absolute
improvement of at least 2 units compared with baseline in at least
three of the four domains of the ASAS20 criteria, with no
deterioration in the remaining domain. These indices have
demonstrated adequate reliability, validity, and responsiveness
to change.
NSAIDs have been proven efficacious, in both short-term and
extended treatment, in improving the signs and symptoms of AS
in multiple randomized controlled trials (RCTs). Therefore, NSAIDs
continue to be a mainstay of therapy. A recent review pooling
results of four NSAID trials indicated that NSAIDs were superior to
placebo in improving spinal pain, peripheral arthritis, and function
in AS patients over a 6-week period (Zochling et al. 2006a).
Although a number of NSAIDs have been tested, no single agent
has proven more advantageous than another in head-to-head
trials. Comparable effectiveness in the alleviation of spinal pain
and improvement in function has been documented with
cyclooxygenase-2 (COX-2) selective inhibitors (Zochling et al.
2006a). The effect of these drugs on peripheral arthritis in AS
patients has not been studied directly.
Alternative therapies, such as DMARDs, which are successful in
the treatment of other autoimmune arthritides such as RA, offer
minimal benefit in the treatment of AS as regards spinal
involvement. In the majority of RCTs, low-dose methotrexate
had no effect in patients with AS with predominantly axial
manifestations (Chen et al. 2006). A more recent, open-label trial
also demonstrated nonsignificant improvement in ASAS20
score, physician-performed spinal pain score, QOL, and patient
and physician global assessments with higher doses of
methotrexate (Haibel et al. 2007a). In the same study, a
subgroup of patients with peripheral arthritis did report a
decrease in the number of swollen joints, but again the results
were not significant.
The role of sulfasalazine in the treatment of AS has been
controversial. A recent Cochrane systematic review of RCTs
concluded that sulfasalazine may have some benefit in reducing
erythrocyte sedimentation rate (ESR, which may correlate with
disease activity in AS) and decreasing spinal stiffness, but no
evidence of benefit in pain, spinal mobility, physical function, or
patient and physician global assessment (Chen & Liu 2006). This
was also validated in patients with early AS (<5 years’ disease
duration), although a small subset of patients did report
improvement in inflammatory back pain (Braun et al. 2006a).
Although sulfasalazine appears to play little role in suppressing
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peripheral arthritis (Kirwan et al. 1993). In an extended 3-year
study, AS patients had significantly fewer episodes of peripheral
arthritis during therapy with sulfasalazine compared with placebo.
A larger trial examining patients with AS, psoriatic arthritis, and
reactive arthritis showed no benefits with sulfasalazine in
manifestations of axial disease but a significant response in
peripheral arthritis compared with placebo (Clegg et al. 1999).
An open-label trial of leflunomide in AS patients did exhibit
significant improvement in peripheral arthritis (Haibel et al. 2005).
However, the number of patients was small (n=10) and no
significant changes in axial symptoms or other clinical parameters
(patient and physician global assessment, QOL) were
demonstrated. In a randomized, placebo-controlled trial,
leflunomide failed to achieve a 20% response rate as
recommended by the ASAS working group (van Denderen et al.
2005). In addition, no significant differences in peripheral arthritis
were seen in the leflunomide group compared with placebo.
The bisphosphonate pamidronate has been investigated in AS
with conflicting results. RCTs in NSAID-refractory patients have
shown greater improvement in spinal pain and function at a dose
of 60 mg versus 10 mg (Maksymowych et al. 2002). The study
was not adequately powered to confirm the effect of pamidronate
on peripheral arthritis and no further studies have yet examined
this as a primary outcome.
Thalidomide has been tried in patients with severe, refractory AS.
In a 6-month, open-label trial, the mean BASDAI score and
inflammatory markers, C-reactive protein (CRP) and ESR,
significantly decreased with thalidomide therapy (Wei et al. 2003).
A second study also demonstrated significant improvement
(>20%) in four of seven primary indices at 1 year (Huang et al.
2002). However, a high incidence of side effects including
dizziness, dry mouth, nausea, and headache has limited the use
of thalidomide.
Physiotherapy is clearly beneficial for AS patients and should be
incorporated early in treatment. However, a standardized exercise
protocol has not been established and current studies illustrate a
variety of therapy combinations that have shown effectiveness.
For example, one RCT examined the effect of a 3-week spa
exercise program followed by group physiotherapy versus group
physiotherapy alone (van Tubergen et al. 2001). At 12 weeks,
patient function in the spa-treated group was significantly better
compared with patients who only received group physiotherapy.
TNF blockade has proven successful in the treatment of AS. The
first two TNF inhibitors approved for use in AS were etanercept, a
dimeric fusion protein of the TNF receptor linked to the Fc portion
of human IgG1, and infliximab, a chimeric monoclonal antibody
specific for TNF. Pooled results from RCTs have confirmed
substantial improvement in spinal pain and function with both
etanercept and infliximab (Zochling et al. 2006a). Moderate to
significant improvements were also documented in peripheral
arthritis, morning stiffness, enthesitis, chest expansion, ESR,
and CRP.
Unmet needs
Although some traditional treatments for AS have established
efficacy, not all AS patients show benefit. In a cross-sectional
study, more than 20% of AS patients reported insufficient pain
control with NSAIDs, and more than 40% required a change of
NSAID due to lack of efficacy (Zochling et al. 2006b).
Furthermore, multiple side effects associated with NSAIDs have
limited their use. In the study by Zochling et al. (2006b), more than
half of treated patients reported adverse events. GI and cardiac
toxicity remain the greatest safety concerns. GI toxicity appears
to be dose-dependent, and symptoms can range from mild
diarrhea and dyspepsia to severe GI bleeding or peptic ulceration
(Lewis et al. 2002). Although the absolute risk is low, the
cardiovascular toxicity of NSAIDs and COX-2 inhibitors has been
an area of intense discussion (Solomon et al. 2005).
An important unmet need as regards the optimal treatment of AS
is that quite a number of patients suffer the disease for long
periods of time, in many cases years, before the diagnosis is
established. This substantial delay in diagnosis of AS remains
problematic. As a result, many patients already have structural
damage at presentation (Khan 2002). This is important as recent
studies suggest that patients treated with TNF inhibitors at earlier
stages of disease may have better responses to therapy and,
therefore, less disease progression (Rudwaleit et al. 2004). An
additional concern noted during treatment with other TNF
inhibitors is that therapy does not lead to long-term treatment-
free remission. Thus, the majority of AS patients who achieve
good control of the signs and symptoms of disease while on a
TNF inhibitor and who then stop therapy typically need to restart
therapy, often in as little as 1.5–4.5 months after initially stopping
(Brandt et al. 2003; Baraliakos et al. 2005). Finally, MRI has shown
significant improvement in spinal inflammation in patients with AS
treated with TNF inhibitors (Haibel et al. 2006a). However,
evidence of the impact of adalimumab and other TNF inhibitors
on structural changes or disease progression by MRI has yet to
be fully delineated.
Clinical evidence with adalimumab in AS
Clinical outcomes
There is clear evidence from clinical trials that treatment with
adalimumab significantly improves disease-associated outcomes
in AS.
Improvement in ASAS criteria
Clinical response to adalimumab in AS has most often been
evaluated using the ASAS20 response criteria (Brandt et al. 2004).
ASAS40 response criteria have also been used. Other validated
parameters include the ASAS5/6 response criteria (Brandt et al.
2004), which were developed for clinical trials and used initially in
trials of TNF inhibitors. The ASAS5/6 require at least 20%
improvement in five of six domains: spinal mobility as assessed
by the Bath Ankylosing Spondylitis Metrology Index (BASMI)
(other instruments may be used) (Jenkinson et al. 1994); CRP
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level; and the four domains included in the ASAS20 response
criteria. Although the ASAS5/6 criteria are commonly utilized, the
clinical advantage of a 20% improvement in these additional
domains remains unclear (van der Heijde et al. 2005). Therefore, it
has been recommended that the ASAS40 criteria continue to be
assessed in conjunction with the ASAS5/6.
The significant improvement in AS patients with the use of TNF
inhibitors has also led researchers to institute criteria for higher
levels of response or “partial remission.” Partial remission is
defined as a value of <2 on a 0–10 scale in each of the four
domains of the ASAS20 (Anderson et al. 2001). It is important to
note however, that the criteria were developed on the basis of
clinical trials with NSAIDs and although validated against expert
opinion, may not be as clinically relevant if applied to response
with TNF inhibitors (Zochling & Braun 2006).
The effectiveness of adalimumab in achieving ASAS responses
was first investigated in a small, open-label trial of 15 patients
with moderate to severe disease over a 52-week period (Haibel et
al. 2006a). Of the 13 patients who completed the study, 67%
achieved an ASAS40 response at 52 weeks (Table 2). Extension of
treatment with adalimumab to 2 years in this group of patients
resulted in persistent levels of ASAS40 response (Haibel et
al. 2006b).
The success of the original open-label study lead to larger,
more stringent double-blind, placebo-controlled, randomized
clinical trials (Tables 2 and 3). The multicenter study
Adalimumab Trial Evaluating Long-term Efficacy and Safety in
Ankylosing Spondylitis (ATLAS) compared placebo with a
subcutaneous injection of adalimumab 40 mg every other week
for 24 weeks (van der Heijde et al. 2006a). The primary efficacy
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Outcome Reference Design Treatment Results
BASDAI (>50%
improvement)
Haibel et al. 2006a OL, 52 wk, 15 pts Ada 40 mg qow >50%
Haibel et al. 2006b OL, 104 wk extension, 15 pts Ada 40 mg qow 67%
van der Heijde et al. 2006a DBPCRCT, 24 wk, 315 pts Ada 40 mg qow
vs placebo
Ada: 42.3%a
Placebo: 15%
ASAS20/ASAS40 Haibel et al. 2006a OL, 52 wk, 15 pts Ada 40 mg qow 73% (ASAS20);
67% (ASAS40)
Haibel et al. 2006b OL, 104 wk extension, 15 pts Ada 40 mg qow 73% (ASAS20);
60% (ASAS40)
van der Heijde et al. 2006a DBPCRCT, 24 wk, 315 pts Ada 40 mg qow vs
placebo
Ada: 51% (ASAS20)a; 39.4%
(ASAS40)a
Placebo: 18% (ASAS20); 13.1%
(ASAS40)
van der Heijde et al. 2007b DBPCRCT, 24 wk, 11 pts TSA
subgroup
Ada 40 mg qow
vs placebo
Ada: 100% (ASAS20); 50% (ASAS40)
Placebo: 0% (ASAS20); 0% (ASAS40)
van der Heijde et al. 2007a DBPCRCT, 104 wk extension, 315 pts
all switched to OL at 24 wk
Ada 40 mg qow
vs placebo
Ada: 79% (ASAS20); 67% (ASAS40)
Haibel et al. 2007b DBPCRCT, 12 wk with OL extension
to 20 wk, 46 pts with early AS
Ada 40 mg qow
vs placebo
12 wk Ada: 68% (ASAS20); 54%
(ASAS40)
12 wk placebo: 21% (ASAS20); 12%
(ASAS40)
20 wk Ada: 68% (ASAS20); 45%
(ASAS40)
20 wk placebo switched to OL Ada:
71% (ASAS20); 58% (ASAS40)
ASAS5/6 van der Heijde et al. 2006a DBPCRCT, 24 wk, 315 pts Ada 40 mg qow
vs placebo
24 wk Ada: 44.7%
24 wk placebo: 12.3%
24 wk Ada in pts with TSA: 75%
24 wk placebo in pts with TSA: 0%
van der Heijde et al. 2007a DBPCRCT, 104 wk extension, 11 pts
TSA subgroup
Ada 40 mg qow
vs placebo
Ada: 38%
aP<0.001 vs placebo.
Ada, adalimumab; AS, ankylosing spandylitis; ASAS, ASsessment in Ankylosing Spondylitis; BASDAI, Bath Ankylosing Spondylitis Activity Index; DBPCRCT, double-blind placebo-controlled
randomized clinical trial; OL, open-label; pts, patients; qow, every other week; TSA, total spinal ankylosis; wk, week.
Table 2 | Efficacy of adalimumab in patients with AS based on ASAS and BASDAI criteriaendpoint was the percentage of patients achieving an ASAS20
at 12 weeks. Secondary outcome measures included the
ASAS20 response at week 24 and the ASAS40 response,
ASAS5/6 response, and percentage of patients achieving
partial remission at weeks 12 and 24. Early escape to open-
label adalimumab therapy was allowed for patients not
achieving an ASAS20 at weeks 12, 16, or 20. At week 12, 58%
of patients in the adalimumab group achieved an ASAS20
and response was documented as early as 2 weeks. Of the
74 placebo recipients that elected early escape, >59% rapidly
became ASAS20 responders at week 16 with adalimumab
treatment. Comparatively, of the 81 patients who had
previously received adalimumab during the double-blind
portion of the study, almost 40% also became ASAS20
responders at week 16 with open-label adalimumab. The
response rates for both groups increased over the remaining
weeks. Furthermore, adalimumab-treated patients had
significantly higher ASAS40, ASAS5/6, and partial remission
responses at both time points compared with placebo.
Results were subsequently reported from a further open-label
extension of the ATLAS study extended to 104 weeks (van der
Heijde et al. 2007a). Of the initial trial patients, more than 55%
remained in the study. ASAS20 and ASAS40 response was
preserved in the adalimumab group and a significant number of
placebo patients who elected early escape at 24 weeks achieved
an ASAS20 at both 52 and 104 weeks. Partial remission response
also increased with adalimumab treatment from 22 to 39%,
indicating persistent improvement with continued treatment at
104 weeks.
As noted, the diagnosis of AS is often delayed. Some patients
may already have substantial disease progression, for example
bony ankylosis of the vertebrae, by the time they are referred for
rheumatologic evaluation and treatment. Therefore, it is
particularly noteworthy that a subset of patients with total spinal
ankylosis (TSA) was included in the ATLAS study. Importantly,
these patients still demonstrated improvement in ASAS
responses. For this small percentage of patients, 50% (three of
six) of the adalimumab-treated group achieved an ASAS20
response at week 12 compared with none of the patients
receiving placebo. Figures improved to 66.7% of patients in the
adalimumab-treated group at week 24, while the percentage of
placebo patients responding remained at zero. These findings are
noteworthy, indicating that AS patients with longstanding disease
may also benefit from TNF-inhibitor therapy. The efficacy of
adalimumab was also maintained in patients with TSA at 2 years
(ASAS20 was achieved by 75% of patients) (van der Heijde et al.
2007a).
Adalimumab may also be beneficial in patients with early AS. In a
recent placebo-controlled study, the diagnosis of early AS or
preradiographic axial spondyloarthritis was defined as the
presence of at least two of three clinical parameters, including
inflammatory back pain, HLA-B27 positivity, and an MRI showing
acute inflammation of the spine or sacroilitis (Haibel et al. 2007b).
A total of 46 patients meeting these criteria were randomized to
placebo or adalimumab biweekly for 12 weeks followed by an
open-label extension. Patients treated with adalimumab had
statistically significantly higher ASAS20 and ASAS40 scores at
12 weeks compared with placebo (68 and 55% versus 21 and
13%). Partial remission was also achieved in >22% of
adalimumab patients. Efficacy remained stable through week 20.
In addition, >70% of patients who originally received placebo
achieved an ASAS20 after only 8 weeks of adalimumab treatment.
Improvement in BASDAI
The BASDAI is a well-established, reliable, and validated
qualitative and quantitative method for determining disease
activity in AS (Garratt et al. 1994). In earlier studies, the BASDAI
was often assessed as a primary outcome. However, in
adalimumab trials, it has largely been replaced by the ASAS
criteria and is now frequently appraised as a secondary outcome.
Improvement in BASDAI (as a primary outcome) with adalimumab
was documented in the initial open-label trial by Haibel et al.
(2006a). Later, in the ATLAS study, BASDAI (as a secondary
outcome measure) demonstrated significant and sustained
improvement at 104 weeks in the adalimumab-treated patients
compared with placebo (van der Heijde et al. 2007b).
Quality of Life
Familiar instruments for the assessment of QOL in AS patients
include the Short Form 36 (SF-36) Health Survey and the
Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL). The
SF-36 was originally developed for application in chronic disease
populations and incorporates a Physical Component Summary
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Reference Design Treatment Results
Haibel et
al. 2007b
DBPCRCT, 12 wk with
OL extension to 20 wk,
46 pts with early AS
Ada 40 mg
qow
12 wk Ada: 22.7%
12 wk placebo: 0%
20 wk Ada: 22.7%
20 wk placebo
switched to OL Ada:
41.7%
van der
Heijde et
al. 2006a
DBPCRCT, 24 wk,
315 pts
Ada 40 mg
qow vs
placebo
24 wk Ada: 22.1%
24 wk placebo:
5.6%
24 wk Ada in pts
with TSA: 0%
24 wk placebo in pts
with TSA: 0%
van der
Heijde et
al. 2007a
DBPCRCT, 104 wk
extension, 315 pts all
switched to OL at 24 wk
Ada 40 mg
qow vs
placebo
Ada: 39%
Placebo: 0%
van der
Heijde et
al. 2007b
DBPCRCT, 24 wk,
11 pts TSA subgroup
Ada 40 mg
qow vs
placebo
Ada: 0%
Ada, adalimumab; AS, ankylosing spondylitis; DBPCRCT, double-blind placebo-controlled
randomized clinical trial; OL, open-label; pts, patients; qow, every other week; TSA, total
spinal ankylosis; wk, week.
Table 3 | Efficacy of adalimumab in patients with AS based on
partial remission rates301
(PCS) score and a Mental Component Summary (MCS) score. The
PCS and MCS each include four domain scores including
physical function, pain, general overall health, and social function
(Davis et al. 2007). Both summary scores and domain scores have
proven reliability and validity in AS populations (Dagfinrud et al.
2004). The ASQoL was developed specifically for AS patients to
assess the current impact of AS on their QOL. The 18-item
disease-specific questionnaire has exhibited sufficient construct
validity and reliability in multiple studies (Haywood et al. 2003).
Health-related quality of life (HRQOL) measures in AS are
important in assessing several areas of patient wellbeing
including physical, psychologic, mental, and social. The impact of
improvement in these outcomes is even greater when paralleled
by significant improvements in clinical outcomes. In the ATLAS
trial, HRQOL was measured by the SF-36 Health Survey at
baseline, 12 weeks, and 24 weeks, and by the ASQoL
questionnaire at baseline and weeks 2, 12, and 24 (Davis et al.
2007). Overall, adalimumab-treated patients had statistically
significant improvements in SF-36 and ASQoL scores compared
with placebo patients at week 12 (Table 4). These improvements
occurred as early as 2 weeks after initiating treatment with
adalimumab and persisted through week 24. The improvements
in HRQOL were considered clinically meaningful as the mean
change from baseline in SF-36 scores at both 12 weeks and
24 weeks exceeded the a priori minimum important difference
(MID) of three points for the adalimumab group but not for the
placebo group. Furthermore, there was significant association
between HRQOL improvements and ASAS clinical responses.
Adalimumab also improves physical functioning and work
productivity in AS patients (van der Heijde et al. 2006a). After
24 weeks of treatment, patients receiving adalimumab reported
greater improvement versus placebo in BASFI and SF-36 scores.
Work productivity, as measured by the Work Productivity and
Activity Impairment-Specific Health Problem (WPAI-SHP)
questionnaire, correlated significantly with these scores. In
addition, duration of exposure to adalimumab and baseline
disease activity BASDAI score were significant predictors of
improvement of overall work productivity loss at week 24
from baseline.
Improvements in MRI
Clinical benefit in AS patients treated with adalimumab has been
paralleled by improvements in spinal inflammation and sacroilitis
assessed by MRI. Recently, a small study examined the effects of
6 months of adalimumab therapy on acute spinal changes in eight
AS patients using the Ankylosing Spondylitis Spine MRI-a
(ASspiMRI-a) scoring system (Carrasco et al. 2007). Results were
compared with changes in clinical and biologic variables including
CRP, BASFI, BASDAI, and patient and physician global
assessments. Statistically significant improvement was
documented in all variables except CRP. ASspiMRI-a median
score was significantly lower than baseline after 24 weeks of
adalimumab therapy.
A phase III trial examined the effects of adalimumab versus
placebo by MRI on both spinal and sacroiliac joint inflammation in
AS patients (n=82) over a 52-week period (Maksymowych et al.
2006). Inflammation was measured by the Spondyloarthritis
Research Consortium of Canada (SPARCC) MRI index. In the
adalimumab-treated group, mean percent change in the SPARCC
score of the spine and sacroiliac joints was –50 and –52% at
52 weeks. After week 24, placebo patients were switched to
open-label adalimumab and had improved SPARCC scores
comparable to the adalimumab group by week 52.
Safety
Adalimumab has shown an acceptable safety profile specifically
in AS patients. In the ATLAS trial, adverse event rates per
100 patient years were compared at 24 weeks (double-blind
phase) and after 2 years of adalimumab exposure (van der Heijde
et al. 2007a). The rate of serious adverse events at the two time
points was 10.2 and 10.5%. At 24 weeks, there were no serious
infections reported. This increased to a rate of only 1.1% at
2 years of treatment. Adverse events leading to discontinuation of
the study did not increase significantly (3.8 and 4.5%). After 104
weeks’ treatment, adverse events occurring at a frequency of 5%
or more included nasopharyngitis, upper respiratory tract
infection, and headache. Of note, there were no cases of
tuberculosis, lupus-like symptoms, demyelinating disease, or
death during the 2-year study.
Economic evidence
The economic evidence for the use of adalimumab in AS is
limited to the models summarized in a NICE technology
appraisal (NICE 2007) and one analysis investigating the cost
efficacy of adalimumab for treatment of AS in the UK (Botteman
et al. 2007).
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Design Treatment Outcome Results
DBPCRCT,
24 wk, 315
pts
Ada 40 mg qow vs
placebo
SF-36 PCS 12 wk achieving a
priori MID:
Ada: 65%
Placebo: 37.6%
24 wk:
Ada: 67.3%
Placebo: 39.6%
ASQoL 12 wk achieving a
priori MID:
Ada: 59.6%
Placebo: 42.1%
24 wk:
Ada: 65.4%
Placebo: 42.1%
Ada, adalimumab; AS, ankylosing spondylitis; ASQoL, Ankylosing Spondylitis Quality of
Life Questionnaire; DBPCRCT, double-blind placebo-controlled randomized clinical trial;
MID, minimum important difference; PCS, physical component summary; pts, patients;
qow, every other week; SF-36, short form-36; wk, week.
Table 4 | Effect of adalimumab on quality of life in patients with
AS (Davis et al. 2007)The NICE technology appraisal includes a model from the
manufacturer of adalimumab, and their own. The manufacturer’s
economic evaluation uses a patient-based transition-model,
which compares the use of adalimumab plus NSAIDs versus
treatment with NSAIDs alone. Patient-level data from the
Canadian AS (Maksymowych et al. 2005) and the ATLAS (van der
Heijde et al. 2006a) phase III trials were included, and helped to
simulate treatment decisions based on the British Society for
Rheumatology (BSR) guidelines. Unlike these recommendations,
the study populations included patients who had responded
inadequately to fewer than two NSAIDs. The model considered
both short-term trial data for responders or nonresponders and
long-term outcomes for adalimumab responders. In the short-
term component of the model, BASDAI and BASFI scores
remained stable as long as the patients were treated with
adalimumab. In contrast, BASFI scores of patients on standard
therapy were assumed to increase by 0.05 units/year.
Assumptions were made that discontinuation of adalimumab
treatment would return BASDAI and BASFI scores to the average
values of those patients in the model managed by conventional
therapy, and that the discontinuation rate would be approximately
10% per year. Disease-specific costs were based on ordinary
least squares (OLS) regression of BASDAI and BASFI data from
OASIS (Boonen et al. 2003). Only BASDAI measurements were
used to estimate costs in the base case analysis.
The incremental cost-effectiveness ratios (ICERs) varied from
ﾣ18 000 to around ﾣ27 000 (over 30 years). Moreover, a BASFI-
based scenario estimated the ICERs at ﾣ29 000 (5 years) and
ﾣ25 300 (10 years). The NICE Technology Assessment Group
investigated the use of adalimumab, etanercept, and infliximab
versus “conventional treatment” in a cohort of 1000 patients. The
cost effectiveness of these interventions in the short term (1 year)
and over a time horizon up to 20 years was estimated. The short-
term model used weekly cycles for its Markov-like transitions, and
the long-term model (2–20 years) was based on quarterly cycles.
They assumed that all three interventions were of equal
effectiveness, and that the differences in costs were consequently
driven by issues related to their relative acquisition and
administration costs. The short-term model used the response
rates from the pooled week 12 data from the adalimumab,
etanercept, and infliximab trials. Several assumptions were made
in terms of spontaneous recovery rate and annual TNF withdrawal
number. As in the manufacturer’s model, disease-related costs
were based on OLS regression of BASDAI and BASFI data from
OASIS. BASFI was used as the major predictor of costs. For the
long-term estimations, the model explored two alternative
scenarios for BASFI progression on treatment: BASFI progression
continues while on TNF inhibitor treatment, and no increase in
BASFI score while on treatment.
In the first year of treatment, the ICER in cost per quality-adjusted
life-year (QALY) gained was approximately ﾣ55000 for
adalimumab and etanercept, and the ICER for infliximab was over
ﾣ120 000. Due to the assumptions made by the Assessment
Group regarding spontaneous recovery of patients given
conventional therapy, cost estimations in the long-term modeling
demonstrated steadily increasing ICERs from year 2 onwards.
However, multiway sensitivity analysis identified scenarios in
which adalimumab/etanercept could be cost effective, with ICERs
around ﾣ20 000.
Botteman and colleagues (2007) evaluated the cost effectiveness
of adalimumab versus conventional therapy in patients with active
AS from the perspective of the NHS in the UK. The authors
estimated direct medical costs and QALYs for three time periods,
namely 48 weeks, 5 years, and 30 years. Indirect costs and other
costs were considered in a separate scenario. The analysis was
pooled on data from the ATLAS and the Canadian AS phase III
trials. A microstimulation model was developed for the
adalimumab group according to the International ASAS
Consensus Statement and BSR guidelines. Using the pooled
adalimumab data, as well as data from the OASIS database and
the literature, they created a model to estimate patients’ BASDAI
and BASFI scores, costs, and HRQOL associated with various
degrees of disease activity. Calculations (in 2004 ﾣUK) were made
from the perspective of the UK NHS regarding costs of drugs,
administration, monitoring, hospitalization, and adverse events.
All costs and benefits for economic and clinical outcomes were
discounted at the rate of 3.5% per annum. The ICER per QALY of
adalimumab versus conventional therapy was estimated to
improve with longer time horizons, namely from ﾣ47083
(48 weeks) to ﾣ23 097 (30 years). Including indirect costs, the
ICER improved to ﾣ5093 per QALY. The analysis suggests that
adalimumab is cost effective for the treatment of AS according to
BSR guidelines relative to conventional therapy from the
perspective of the UK NHS.
Resource utilization
Truly effective therapeutic options for AS had been quite limited for
a long time. Conventional treatment modalities may have had an
effect on pain and other symptoms, but did not alter the progression
of disease and had no effect on the spinal manifestations. The high
efficacy of the expensive TNF blockers, including adalimumab, for
the treatment of AS demonstrated a breakthrough for NSAID-
refractory patients. Despite their clinical efficacy, the relatively high
acquisition costs of TNF inhibitors are of potential concern. As
presented above, economic data on adalimumab in AS are limited,
and its long-term effect on the burden of the disease is unknown.
Long-term controlled trials are necessary to confirm the benefits of
the anti-TNF therapy, particularly regarding the maintenance of
improvements in functional status/QOL, the effect on disease
progression, and, of course, safety. Moreover, adalimumab has also
shown efficacy for extrarheumatic manifestations frequently
occurring in patients with AS, such as psoriasis, Crohn’s disease,
and anterior uveitis (Kavanaugh et al. 2006). The notable clinical
efficacy of adalimumab needs to be factored into a comprehensive
assessment of value, particularly considering the fact that
effectiveness and cost-effectiveness analyses of the TNF inhibitors
mostly assessed AS-specific outcomes and did not fully capture any
possible effects of treatment on nonskeletal manifestations of AS.
The cost efficacy of anti-TNF therapy will depend on whether
treatment can alter the clinical course and avoid long-term
disability. As demonstrated in the BeSt trial for early RA, early
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aggressive treatment with infliximab resulted in earlier functional
improvement and less radiographic damage (Goekoop-Ruiterman
et al. 2005, 2007), and the sequential or early use of TNF
antagonists may also play an important role in the future for
patients with AS. Diagnosing and treating AS patients earlier will
be a major challenge for many clinicians and an important strategy
for the prevention of long-term damage and loss of function.
Future cost effectiveness and other analyses will be crucial to
assess the optimal use of the newer therapies. It will be important
that the models used focus on the drug’s effect on direct and
indirect costs, and particularly on productivity and employability in
patients with AS. Additional health economic implications may
play a role in the future, when more anti-TNF agents could be
brought to the clinic. The introduction of additional agents
combined with market forces may help lower their costs.
Patient group/population
Adalimumab is currently approved by the FDA for the treatment of
adult patients with chronic severe AS who have inadequate
response to conventional therapy. International criteria for the use
of TNF inhibitors in AS were recently updated (Braun et al. 2006b)
and recommended the following revisions for the initiation of anti-
TNF treatment: a diagnosis of definitive AS (based on the
modified New York criteria) and active disease for at least 4 weeks
as defined by a sustained BASDAI ≥4 on a 0–10 scale and expert
opinion based on clinical findings; refractory disease, defined by
failure of ≥2 NSAIDs during a 3-month period, failure of
intraarticular steroids (if indicated), and failure of sulfasalazine in
patients with predominantly peripheral arthritis; and application of
the usual precautions and contraindications for biologic
treatment. Guidelines for monitoring anti-TNF treatment were also
updated and recommended that both the ASAS score set for
clinical practice and the BASDAI should be followed after the
initiation of treatment. Discontinuation of anti-TNF treatment in
nonresponders should be considered after 6–12 weeks. Lastly,
response would be defined by improvement of at least 50% or
2 units (on a 0–10 scale) of the BASDAI (Braun et al. 2006b). In the
UK, guidelines for the use of TNF inhibitors from the BSR include
only etanercept and infliximab (Keat et al. 2005), although the
BSR has approved the use of adalimumab for patients with active
AS under these guidelines (Anon. 2006). NICE recommends
adalimumab for treatment of AS if the patient satisfies the
modified New York criteria, has a BASDAI score ≥4 and a score of
≥4 cm on the spinal pain VAS demonstrated on two occasions at
least 12 weeks apart, and in whom conventional treatment with
maximum tolerated or recommended dosages of two or more
NSAIDs has failed to control symptoms (NICE 2007).
Adalimumab was the first TNF antagonist to be tested in, and has
demonstrated clinical efficacy in, patients with so-called
“preradiographic axial spondyloarthritis” (Haibel et al. 2007b). A
substantial number of these patients achieved partial remission,
indicating that TNF inhibitors such as adalimumab may be more
effective in patients with early disease and shorter disease
duration. It has also been observed that patients with elevated
CRP or greater amounts of inflammation on MRI may respond
better to TNF inhibitors (Maksymowych et al. 2006; van der Heijde
et al. 2006b). At the other end of the spectrum, analysis of data
from studies of adalimumab has shown that TNF-inhibitor therapy
can show important clinical benefit even in patients with total
spinal ankylosis (van der Heijde et al. 2007b).
Few studies have examined the effects of adalimumab on
extraarticular manifestations in AS. A recent retrospective study
reported that treatment with adalimumab can reduce the number
of uveitis flares in AS patients (Guignard et al. 2006). Another
study evaluating the effects of adalimumab therapy on the
prevention of relapse of inflammatory bowel disease showed an
improved odds ratio compared with etanercept, but not infliximab
(Braun et al. 2007). However, due to the small number of
adalimumab patients analyzed in this study, final conclusions
on this matter cannot be stated until further investigations
are undertaken.
Dosage, administration, and formulations
Adalimumab (Humira) is a recombinant, human IgG1 monoclonal
antibody, indicated for the treatment of AS in adults aged
≥18 years. It is available as a sterile, preservative-free solution of
40 mg per 0.8 mL in 1.0 mL, prefilled, single-use syringes, or in a
pen. If refrigerated, it has a shelf life of 18 months. The needle
cover of the prefilled syringe and the pen contain dry natural
rubber, so patients with latex allergies should avoid using
adalimumab (Anon. 2007).
The recommended starting dose is 40 mg injected
subcutaneously every other week (i.e. every 14 days). This dose
can be increased to every week if response is deemed
inadequate. Treatment should be continued up to 12 weeks and
discontinued if the patient does not meet treatment response
criteria at that time. Concomitant treatment with methotrexate or
other DMARDs is not required for efficacy.
Patients are encouraged to self-administer adalimumab.
Common injection sites include the thighs, outer arms, and
abdomen. Injection sites should be cleaned with alcohol prior to
injection and should not be given at the same site consecutively.
Areas where the skin is scarred, inflamed, or broken should
be avoided.
Place in therapy
Although few in number, clinical trials have established the
efficacy of adalimumab in the treatment of AS up to 104 weeks.
Significant improvements compared with placebo have been
documented as early as 2 weeks in both physician-assessed and
patient-assessed outcomes. Substantial decreases in primary
and secondary endpoints such as the BASDAI, ASAS20, ASAS40,
ASAS5/6, and partial remission response criteria have suggested
that the benefit achieved with adalimumab is at least comparable
to that seen with etanercept and infliximab. Adalimumab is also
effective for peripheral arthritis, enthesitis, and extraarticular
manifestations associated with AS, including uveitis and
inflammatory bowel disease. In addition, adalimumab has an
acceptable safety profile in AS patients.
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adalimumab on the AS patient’s QOL. In clinical trials,
adalimumab significantly impacted patient QOL when assessed
by both a disease-specific (ASQoL) and a generic health status
instrument (SF-36). Studies have also shown that there is a
significant correlation between improvements in HRQOL and
ASAS clinical responses. Other parameters that improved with
adalimumab included overall emotional health and fatigue.
Current guidelines recommend adalimumab for the treatment of
severe, active AS. Some evidence from studies of adalimumab
suggests that patients in the early stages of disease or
preradiographic AS have a greater response rate to TNF
inhibitors than patients with established AS. Therefore, earlier
diagnosis of AS may become critical if treatment with biologic
therapy proves to have significant effects on future disease
progression. Furthermore, adalimumab has shown efficacy in
patients with complete ankylosis of the spine. These patients
were previously thought to obtain little benefit from further
treatment. Currently, international criteria do not recommend
treatment with biologics for patients with TSA, but modification
of future standards are expected to recognize this subset
of patients.
Additionally, patients with elevated CRP or ESR or greater
amounts of inflammation on MRI may also exhibit a more
profound response to adalimumab, especially earlier in the
disease course. The extent to which suppression of
inflammation on MRI correlates with attenuation of structural
damage as measured by plain radiography remains to
be elucidated.
Recent European analysis suggests that adalimumab is a cost-
effective treatment for AS compared with conventional therapy.
However, high acquisition costs remain a concern. Economic
data on adalimumab use in AS are limited and its long-term
effect on the burden of disease is unknown. Supplementary
information from further controlled trials, particularly regarding
the maintenance of improvements in functional status and
QOL, structural progression, and safety will also have be
addressed in future calculations of cost effectiveness.
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